Table 2.
Estimated effectiveness of two doses of BNT162b2 (≥7 days after the second dose) against laboratory-confirmed SARS-CoV-2 outcomes by age group (Jan 24 to April 3, 2021)
|
Unvaccinated |
Fully vaccinated* |
Vaccine effectiveness |
||||
|---|---|---|---|---|---|---|
| Cases | Incidence rate per 100 000 person-days† | Cases | Incidence rate per 100 000 person-days‡ | Unadjusted | Adjusted§ | |
| SARS-CoV-2 infection¶ | ||||||
| Age 16–44 years | 84 611 | 95·1 | 1801 | 2·3 | 95·4% (94·0–96·5) | 96·1% (95·7–96·5) |
| Age 45–64 years | 19 579 | 86·1 | 2264 | 3·4 | 93·6% (91·4–95·3) | 94·9% (94·2–95·5) |
| Age ≥65 years | 5686 | 67·7 | 2201 | 3·8 | 93·4% (91·3–95·0) | 94·8% (93·9–95·5) |
| All ages | 109 876 | 91·5 | 6266 | 3·1 | 94·2% (93·2–95·1) | 95·3% (94·9–95·7) |
| Asymptomatic SARS-CoV-2 infection | ||||||
| Age 16–44 years | 40 088 | 45·1 | 1174 | 1·5 | 92·8% (90·3–94·7) | 93·6% (92·8–94·4) |
| Age 45–64 years | 7414 | 32·6 | 1343 | 2·0 | 89·1% (84·7–92·3) | 90·8% (89·6–91·9) |
| Age ≥65 years | 1636 | 19·5 | 1115 | 1·9 | 85·9% (80·2–89·9) | 88·5% (86·4–90·3) |
| All ages | 49 138 | 40·9 | 3632 | 1·8 | 90·1% (88·0–91·8) | 91·5% (90·7–92·2) |
| Symptomatic COVID-19 | ||||||
| Age 16–44 years | 28 196 | 31·7 | 352 | 0·5 | 97·8% (97·0–98·3) | 97·6% (97·3–97·8) |
| Age 45–64 years | 7790 | 34·3 | 560 | 0·8 | 96·3% (95·0–97·3) | 96·7% (96·3–97·0) |
| Age ≥65 years | 3079 | 36·6 | 780 | 1·4 | 96·1% (94·8–97·1) | 96·4% (95·9–97·0) |
| All ages | 39 065 | 32·5 | 1692 | 0·8 | 96·6% (95·8–97·2) | 97·0% (96·7–97·2) |
| COVID-19-related hospitalisation | ||||||
| Age 16–44 years | 2043 | 2·3 | 33 | <0·1 | 98·1% (97·1–98·8) | 98·1% (97·3–98·7) |
| Age 45–64 years | 1687 | 7·4 | 112 | 0·2 | 97·6% (96·9–98·2) | 97·6% (97·1–98·1) |
| Age ≥65 years | 1826 | 21·7 | 451 | 0·8 | 96·6% (95·3–97·6) | 96·8% (96·2–97·3) |
| All ages | 5526 | 4·6 | 596 | 0·3 | 96·7% (95·5–97·6) | 97·2% (96·8–97·5) |
| Severe or critical COVID-19-related hospitalisation | ||||||
| Age 16–44 years | 644 | 0·7 | 7 | 0·01 | 98·8% (97·3–99·5) | 98·9% (97·6–99·5) |
| Age 45–64 years | 1132 | 5·0 | 62 | 0·1 | 98·1% (97·2–98·6) | 98·1% (97·5–98·5) |
| Age ≥65 years | 1425 | 17·0 | 295 | 0·5 | 97·2% (95·9–98·1) | 97·3% (96·8–97·8) |
| All ages | 3201 | 2·7 | 364 | 0·2 | 97·2% (95·9–98·1) | 97·5% (97·1–97·8) |
| COVID-19-related death | ||||||
| Age 16–44 years | 36 | 0·04 | 0 | 0·0 | 100 | 100 |
| Age 45–64 years | 125 | 0·5 | 14 | <0·1 | 96·2% (92·6–98·0) | 95·8% (92·6–97·6) |
| Age ≥65 years | 554 | 6·6 | 124 | 0·2 | 96·8% (94·6–98·1) | 96·9% (96·0–97·6) |
| All ages | 715 | 0·6 | 138 | 0·1 | 96·6% (93·9–98·1) | 96·7% (96·0–97·3) |
Numbers and incidence rates of outcomes are shown for unvaccinated and fully vaccinated individuals. Vaccine effectiveness estimates are % (95% CI).
Defined as people for whom at least 7 days had passed after the second dose of BNT162b2 vaccine.
Total person-days for all outcomes were 88 938 310 for age 16–44 years, 22 734 104 for age 45–64 years, 8 403 722 for age ≥65 years, and 120 076 136 for all ages.
Total person-days for all outcomes were 77 280 829 for age 16–44 years, 67 027 668 for age 45–64 years, 57 573 686 for age ≥65 years, and 201 882 183 for all ages.
Model is adjusted for age group (16–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, and ≥85 years), sex, and calendar week.
Includes asymptomatic and symptomatic infections, as well as cases with positive SARS-CoV-2 tests for which the symptom interview portion of the epidemiological investigation was not completed.